Blueprint Medicines (NASDAQ:BPMC) Reaches New 1-Year Low - Should You Sell?

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) hit a new 52-week low on Thursday . The company traded as low as $73.04 and last traded at $82.05, with a volume of 1903265 shares changing hands. The stock had previously closed at $79.22.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. HC Wainwright reiterated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, February 14th. Wedbush restated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Tuesday, April 8th. Finally, JMP Securities reissued a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and an average price target of $124.95.

Blueprint Medicines Trading Down 2.0 %

The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.17 billion, a PE ratio of -74.86 and a beta of 0.75. The stock has a 50 day moving average price of $90.36 and a 200 day moving average price of $93.47.

Remove Ads

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Sell-side analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Activity at Blueprint Medicines

In other news, insider Ariel Hurley sold 3,203 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the transaction, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total transaction of $250,458.36. Following the completion of the transaction, the chief operating officer now owns 67,109 shares in the company, valued at approximately $7,391,385.26. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,358 shares of company stock valued at $2,583,187 in the last three months. Company insiders own 4.21% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC purchased a new position in Blueprint Medicines in the 4th quarter worth about $103,356,000. Norges Bank purchased a new position in Blueprint Medicines during the fourth quarter valued at approximately $62,028,000. Jennison Associates LLC purchased a new position in shares of Blueprint Medicines during the 4th quarter valued at $31,417,000. Rock Springs Capital Management LP boosted its stake in shares of Blueprint Medicines by 42.7% in the fourth quarter. Rock Springs Capital Management LP now owns 1,096,899 shares of the biotechnology company's stock worth $95,672,000 after acquiring an additional 328,123 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Blueprint Medicines by 8.0% in the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after purchasing an additional 316,754 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.